• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Funding Support Center

DF/HCC Sponsored Funding

Dana-Farber/Harvard Cancer Center (DF/HCC) 
A. David Mazzone Research Awards Program 
Community Outreach Award

Sponsor: Non-Federal (DFCI)
Award Amount: Up to $35,000 per year for two years for direct costs only ($70,000 total).

Application deadline: 04:59:59 PM EST, Friday, June 13, 2014
Funding decisions will be made through peer review by July 15, 2014
Anticipated award date:  August 1, 2014 

--------------------------------------------------
SUBMISSION INFORMATION

Submission requirements: Applications must be submitted online: Application Form Web Page
Applications submitted using other means will not be reviewed or considered for this award. Applicants should notify their grant administrator/office and follow their institutionís policies and procedures for approval to submit applications. Applications will not be accepted after 04:59:59 PM EST, Friday, June 13, 2014.

Please direct questions to: 
Juan Carlos Hincapie
Tel: (617) 632-6155
Emailmazzoneawards@partners.org

OVERVIEW AND PURPOSE

The A. David Mazzone Research Awards Program will fund a series of collaborative and innovative cancer research, career development, community outreach, and training projects to address a range of needs in prostate cancer and Lupron-treatable diseases.

Community Outreach Awards are designed to help Dana-Farber/Harvard Cancer Center develop, implement, evaluate, and disseminate prostate cancer awareness, education, and screening efforts throughout Boston communities which are racially and ethnically diverse and/or underserved. Particular focus should be on African American men who are 60% more likely to develop prostate cancer compared to Caucasian men, and are nearly 2.5 times as likely to die from the disease.

Specific Requirements and Objectives
Applications will be accepted for funding Community Outreach Research (Type 1) and Community Outreach Activities (Type 2).

Type 1: Community Outreach Research Grants in the context of this RFA are hypothesis-driven (either hypothesis testing or hypothesis generating) projects aimed at increasing the use of and access to beneficial treatments, prevention measures, or early detection procedures. Projects must effectively reach individuals and physicians in the Boston area and should increase the use of medical procedures that may result in decreasing prostate cancer disparities. Research studies may include focus groups and needs assessments. Recruitment and retention of racial and ethnic minorities and socio-economically disadvantaged populations into clinical trials is encouraged.

Type 2: Community Outreach Activity Grants in the context of this RFA will develop community outreach activities, such as:

  • Working with community organizations or church networks to reach and educate the citizens of underserved communities about reduction of risk, early detection, and treatment of prostate cancer;
  • Developing continuing education programs for community health care providers to ensure that they are able to offer state-of-the-art care and advice to their patients;
  • Promoting the development and delivery of health promotion and educational activities; training communities on utilizing electronic information systems which educate individuals about prostate cancer and help them make informed decisions about their health.

AWARD INFORMATION

Award is for $35,000 per year for up to two years ($70,000 total in direct costs). The next projected award period is  August 1, 2014 to July 31, 2015. Three awards remain in this category to be awarded over the next two-year period.

Funding Agency: The funding agency for the program is a non-federal grant from the U.S. District Court for the District of Massachusetts. Funding was derived from a pool of unclaimed funds from the settlement in 2004 of a class action suit against TAP Pharmaceuticals. The class action suit was related to marketing and sales practices for the prostate cancer drug Lupron.

The Mazzone Awards Program is a DFCI-sponsored award, administered jointly through DF/HCC and the Prostate Cancer Foundation.

ELIGIBILITY CRITERIA

Applications will be accepted from two or more principal investigators, at least one of whom holds a full-time Harvard faculty appointment at the level of Instructor or higher. Applications including investigators from more than one DF/HCC member institution are encouraged, as are applications that are part of the University of Massachusetts Boston-DF/HCC U54 partnership. Applicants may apply for multiple grants; however, individuals may only be awarded one A. David Mazzone Research Award at a time.

Employees or subcontractors of a government entity or for-profit private industry are not eligible. Exceptions include applicants holding full-time positions at a veterans' hospital or national laboratory (e.g., Lawrence Berkeley National Laboratory) in the United States. Members of the Programís Scientific Advisory Board (SAB) are ineligible to apply.

PROPOSAL SUBMISSION INFORMATION
Required items (5):

  • Application Form: To be completed online by the Principal Investigator when submitting your proposal to the Application Form Web Page. Provide a 250-word abstract description of the project in laymenís terms.
  • Research Proposal: The proposal should describe the research and/or activities to which this award would be applied if funded. Maximum of 3 pages of text including figures. References and budget pages are not included in this page limit. Appendix material will be accepted with the following restrictions: a two-page limit of relevant supporting text or figures; only manuscripts that have been accepted for publication with the journal acceptance letter. Research proposals for both types of community outreach must include an evaluation plan that addresses the effectiveness and impact of the program on the community.
  • Biosketches: Current NIH Biosketch for each participating PI, including all funding sources.
  • Budget: Budget requests (direct costs only) and budget justifications should be submitted as NIH 398 form with major divisions of funds (personnel, equipment, supplies, other, etc.; with adequate rationale). Separate budget pages must be submitted for each individual institution requesting funds. Funds will be distributed directly from DFCI to sub-recipients. A composite budget that includes the total costs of the project should also be included when multiple institutions are involved in the project. PIs may include a level of effort and salary support commensurate with their efforts on the project. Support and effort may be split between the collaborating PIs. Funds may be used for direct research expenses only, which may include salary and benefits of researchers, patient navigators, or community health educators, research/laboratory/educational supplies, and equipment.
  • IRB approval, if applicable, is required prior to funding.

Format: Items 2 Ė 4 (above) must be compiled and submitted as a single PDF file. Please include the PIís name, project title, and page number at the top of each page.

Submit Proposal Online: Application Form Web Page
Application Deadline: 04:59:59 PM EST, Friday, June 13, 2014.
IN FAIRNESS TO ALL THERE WILL BE NO EXCEPTIONS TO THIS DEADLINE

REVIEW CRITERIA
Applications will be reviewed by members of the Programís Scientific Review Board. Grants will be awarded on the basis of the following review criteria (in order of importance):

  • Significance. The project should address an important problem or a critical barrier to progress in the field. The aims of the project should advance scientific knowledge, technical capability, and/or clinical practice and have near-term patient impact.
  • Inter-institutional and Community Links. Proposals that foster inter-institutional collaboration and partnerships with community-based organizations will be favored.
  • Investigators. The PIs, collaborators, and other personnel should have the necessary experience, expertise, and proven track records of accomplishment. The investigators should have complementary and integrated expertise.
  • Innovation. The application should challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions.
  • Approach. The overall strategy, methodology, analyses, and evaluation plan should be well-reasoned and appropriate to accomplish the specific aims of the project.
  • Environment. The scientific environment in which the work will be done should contribute to the probability of success.

ADDITIONAL REVIEW CRITERIA SPECIFIC TO ďTYPE 2Ē PROJECTS 

  • Feasibility and consistency of the proposed project plan with the goals and objectives of the RFA;
  • Appropriateness of activities for establishing effective collaborations/partnerships, and patterns and channels of communication;
  • Rationale for selection of the targeted geographic area and documentation of its cancer control needs including cancer-related behavior risk factors, access and utilization of health care services, and cancer rates;
  • A well designed evaluation plan that will demonstrate effectiveness and/or impact of the activities such as demonstration of increased skill-base, knowledge, or increased access or utilization of cancer control/treatment resources as a result of the activities. 

PROGRESS REPORTS 

Grantees must submit annual progress reports to DF/HCC including detailed narrative updates, accrual reports (if applicable), and expenditure reports. Progress will be measured through the review of progress reports, by the publication of research in academic journals, metrics defined in the evaluation plan, and if relevant, by progress in clinical trial activity. Generally, progress that approximately meets benchmarks, timelines, or specific aims that are set forth within corresponding proposals will be funded on a per year basis through the completion of the grant term. Unanticipated scientific findings that delay research timelines will not exclude grantees from continued funding so long as grantee research is of a high-caliber and within the scope of the original research proposal.

2013 COMMUNITY OUTREACH Mazzone Awards Recipient

Shared Medical Appointments: An Innovative Approach to Prostate Cancer Survivorship Care
PI: Larissa Nekhlyudov, MD, MPH (Harvard Vanguard Medical Associates)
Collaborators: Ann Partridge, MD, MPH (DFCI); Wilmer Roberts, MD, PhD (Harvard Vanguard Medical Associates); Michael Pistiner, MD, MMSc (Harvard Vanguard Medical Associates); Aymen Elfiky, MD, MPH (DFCI); Christopher Recklitis, PhD, MPH (DFCI); Sarah Reed, MPH, MSW (DFCI)

Approximately 200,000 new cases of prostate cancer are diagnosed in the U.S. per year; there are two million survivors. Following diagnosis and treatment, many face physical and psychological long-term and late effects. Since the vast majority are elderly, most have chronic medical conditions that require management. Care may be complicated by involvement of multiple providers. Racial disparities may further affect the quality of care. Our study responds to the existing gaps in the care of prostate cancer survivors, focusing on improving the quality of life and quality of care in a community based setting. Shared medical appointments (SMAs), also known as group visits, offer an interactive and engaging clinical environment for patient care. We will pilot test SMAs with prostate cancer survivors to determine the effect of the intervention on patient-oriented outcomes, such as depression, anxiety, fear of recurrence, quality of life and communication. We will also develop and pilot test a medical record abstraction tool to evaluate health care utilization and quality of care. The multidisciplinary, multi-institutional project team fosters an academic-community collaboration. The setting for the intervention is community-based, with a large representation of elderly prostate cancer survivors, the majority being African American. Our approach is innovative and is based on a strong theoretical framework. Both the survey and the medical record abstraction findings will provide preliminary data that will lead to a future large scale study evaluating the potential of SMAs in transforming prostate cancer survivorship care in a racially diverse community-based patient population.

2012 COMMUNITY OUTREACH Mazzone Awards Recipient

Engaging African American Faith Communities in Prostate Cancer Education 
PI: Jennifer Allen (Dana-Farber Cancer Institute)
Collaborator: Donna Berry (Dana-Farber Cancer Institute)

African American (AA) men are 60% more likely to be diagnosed and 2.5 times more likely to die from prostate cancer than White men. They are also diagnosed at younger ages, in later stages, and have poorer survival compared to White men. The proposal addresses an imperative need to facilitate decisions about prostate cancer screening in the wake of conflicting recommendations from national organizations. Such decisions are particularly complex for AA men, given heightened disease risk, diminished access to health services, and medical mistrust. This studyís goal is to pilot test a personally tailored, web-based, interactive educational intervention among AA men and women through churches. Objectives of the intervention are to increase knowledge about prostate cancer and screening, and to promote self-efficacy regarding shared decision-making with oneís medical provider about screening. We include women as they are trusted sources of information for men. Working with a large network of AA churches, we will recruit 30 men and 30 women to pilot test the educational tool. Participants will be interviewed before and after use of the tool to detect changes in knowledge, attitudes toward screening, and, among men, confidence to participate in shared decision-making with onesí provider and intention to undergo screening. This study is novel in its use of web-based interactive technology to provide individualized education about prostate cancer screening to both men and women. Funding from the Mazzone Award will enable us to gather the necessary preliminary data to develop a trial of this intervention on a larger scale.